Glucagon-like peptide-1: A potent regulator of food intake in humans

Gut

Volumn 44, Issue 1, 1999, Pages 81-86

  Gutzwiller, J P ^b   Goke B ^c   Drewe, J ^a   Hildebrand, P ^a   Ketterer, S ^a   Handschin, D ^a   Winterhalder, R ^b   Conen, D ^b   Beglinger, C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Food intake; Glucagon like peptide 1; Hunger and fullness score; Satiety

Indexed keywords

CHOLECYSTOKININ; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; LEPTIN; PLACEBO;

ADULT; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FLUID INTAKE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; HUNGER; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY;

EID: 0002300343     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.1.81     Document Type: Article

References (40)

1. 1 Smith GP, Gibbs J. Brain-gut peptides and the control of food intake. In: Martin JB, Reichlin S, Bick KL, eds. Neurosecretion and brain peptides. New York: Raven, 1981:389-95.
2. 2 Gibbs J, Smith GP. Satiety: the roles of peptides from the stomach and the intestine. Fed Proc 1986;45:1391-5.
3. 3 Gibbs J, Smith GP. The actions of bombesin-like peptides on food intake. Ann N Y Acad Sci 1988;547:210-16.
4. 4 Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973;84:488-95.
5. 5 Bado A, Rodriguez M, Lewin MJM, et al. Cholecystokinin suppresses food intake in cats: structure-activity characerization. Pharmacol Biochem Behav 1988;31:297-303.
6. 6 Weller A, Smith GP, Gibbs J. Endogenous cholecystokinin reduces feeding in young rats. Science 1989;247:1589-91.
7. 7 Silver AJ, Flood JF, Song AM, et al. Evidence for a physiological role for CCK in the regulation of food intake in mice. Am J Physiol 1989;256:R646-52.
8. 8 Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.
9. 9 Lieverse RJ, Jansen JBMJ, Masclee AAM, et al. Satiety effects of cholecystokinin in humans. Gastroenterology 1994;106:1451-4.
10. 10 Kissileff HR, Pi-Sunyer X, Thornton J, et al. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981;34:154-60.
11. 11 Gutzwiller JP, Drewe J, Hildebrand P, et al. Effect of intravenous human gastrin-releasing peptide on food intake in humans. Gastroenterology 1994;106:1168-73.
12. 12 Herrmann C, Göke R, Richter G, et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:117-26.
13. 13 Gutniak M, Ørskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7 36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-22.
14. 14 Nauck MA, Heimesant MM, Ørskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7 36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91:301-7.
15. 15 Welch IML, Sepple CP, Read NW. Comparisons of the effects on satiety and eating behaviour of infusion of lipid into the different regions of the small intestine. Gut 1988;29:306-11.
16. 16 Welch I, Saunders K, Read NW. Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. Gastroenterology 1985;89:1293-7.
17. 17 Drewe J, Gadient A, Rovati LC, et al. Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans. Gastroenterology 1992;102:1654-9.
18. 18 Hashimura E, Shimizu E, Nishino T, et al. Production of rabbit antibody specific for aminoterminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody response. J Immunol Methods 1982;55:375-87.
19. 19 Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996;97:92-103.
20. 20 Schirra J, Kuwert P, Wank U, et al. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 1997;109:84-97.
21. 21 SAS, Release 6.03. Cary, NC: SAS Institute, 1988.
22. 22 Sach L. Angewandte statistik. Berlin: Springer, 1984.
23. 23 Göke R, Larsen PJ, Mikkelsen JD, et al. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294-300.
24. 24 Hörsch D, Göke R, Eissele R, et al. Reciprocal cellular distribution of glucagon-like peptide-1 (GLP-1) immunoreactivity and GLP-1 receptor mRNA in pancreatic islets of rat. Pancreas 1997;14:290-4.
25. 25 Valverde I, Merida E, Delgado E, et al. Presence and characterisation of glucagon-like peptide-1(7 36)amide receptors in solubilized membranes of rat adipose tissue. Endrocrinology 1993;132:75-9.
26. 26 Uttenthal LO, Blazquez E. Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands. FEBS Lett 1990;262:139-41.
27. 27 Schmidtler J, Dehne K, Allescher HD, et al. Rat parietal cell receptors for GLP-1-(7 36) amide: Northern blot, cross-linking, and radioligand binding. Am J Physiol 1994;267: G423-32.
28. 28 Jin SLC, Han VKM, Simmons JG, et al. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988;271:519-32.
29. 20 Salazar I, Vaillant C. Glucagon-like immunoreactivity in hypothalamic neurons of the rat. Cell Tissue Res 1990;261: 355-8.
30. 30 Scrocchi LA, Brown TJ, MacLusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996;2:1254-8.
31. 31 Byrne MM, Göke B. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use. Diabet Med 1996;13:854-60.
32. 32 Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20.
33. 33 Raybould HE, Gaylon RJ, Doekray GJ. Mechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat. J Neurosci 1988;8:3018-24.
34. 31 Wettergren A, Wojdemann M, Meisner S, et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7 36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997;40:507-601.
35. 35 Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-9.
36. 36 Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6.
37. 37 Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
38. 38 Shalev A, Vosmeer S, Keller U. Absence of short-term effects of glucagon-like peptide-1 and of hyperglycemia on plasma leptin levels in man. Metabolism 1997;46:723-5.
39. 39 Todd JF, Wilding JPH, Edwards CMB, et al. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997;27: 533-6.
40. 40 Gutniak MK, Larsson H, Heiber SJ, et al. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Carc 1996;19:843-8.